MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 584598 | Name: Deoxypyridinoline

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Deoxypyridinoline is one of two pyridinium cross-links that provide structural stiffness to type I collagen found in bones. It is excreted unmetabolized in urine and is a specific marker of bone resorption and osteoclastic activity.

Chemical Structure

Deoxypyridinoline
Deoxypyridinoline
CAS#90032-33-0

Theoretical Analysis

MedKoo Cat#: 584598

Name: Deoxypyridinoline

CAS#: 90032-33-0

Chemical Formula: C18H28N4O7

Exact Mass: 412.1958

Molecular Weight: 412.44

Elemental Analysis: C, 52.42; H, 6.84; N, 13.58; O, 27.15

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Deoxypyridinoline; Lysylpyridinoline
IUPAC/Chemical Name
N-(5-Amino-5-carboxypentyl)-3-hydroxy-4-(2-amino-2-carboxyethyl)-5-(3-amino-3-carboxypropyl)pyridine
InChi Key
BSKQHNTXRAANRM-UHFFFAOYSA-N
InChi Code
InChI=1S/C18H28N4O7/c19-12(16(24)25)3-1-2-6-22-14(18(28)29)5-4-10-8-21-9-15(23)11(10)7-13(20)17(26)27/h8-9,12-14,22-23H,1-7,19-20H2,(H,24,25)(H,26,27)(H,28,29)
SMILES Code
O=C(C(NCCCCC(N)C(O)=O)CCC1=CN=CC(O)=C1CC(N)C(O)=O)O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 412.44 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Tabatabaei N, Rodd CJ, Kremer R, Weiler HA. Osteocalcin, but not deoxypyridinoline, increases in response to isoflurane-induced anaesthesia in young female guinea pigs. J Bone Miner Metab. 2015 May;33(3):253-60. doi: 10.1007/s00774-014-0593-7. Epub 2014 May 24. PubMed PMID: 24858976. 2: Shi J, Wang Z, Li H, Yuan H. Diagnostic performance of the urinary deoxypyridinoline in spinal tuberculosis. Orthopedics. 2012 Jun;35(6):e922-6. doi: 10.3928/01477447-20120525-36. PubMed PMID: 22691668. 3: Ochoa-Martínez PY, Hall-Lopez JA, Ávila FA, Rocha CA, Moreira MH, Dantas EH. Effect of three months of periodized hydrogymnastics exercise program on urinary concentration of deoxypyridinoline in older women. Arch Endocrinol Metab. 2015 Dec;59(6):523-7. doi: 10.1590/2359-3997000000102. PubMed PMID: 26677086. 4: Vanderspank D, Bernier SM, Sopper MM, Watson P, Mottola MF. Activity restriction increases deoxypyridinoline excretion in hospitalized high-risk pregnant women. Biol Res Nurs. 2014 Jan;16(1):7-15. doi: 10.1177/1099800412463120. Epub 2012 Oct 17. PubMed PMID: 23079370. 5: Ohishi T, Takahashi M, Kushida K, Horiuchi K, Ishigaki S, Inoue T. Quantitative analyses of urinary pyridinoline and deoxypyridinoline excretion in patients with hyperthyroidism. Endocr Res. 1992;18(4):281-90. PubMed PMID: 1473521. 6: Gaetani P, Tartara F, Tancioni F, Rodriguez y Baena R, Casari E, Alfano M, Grazioli V. Deficiency of total collagen content and of deoxypyridinoline in intracranial aneurysm walls. FEBS Lett. 1997 Mar 10;404(2-3):303-6. PubMed PMID: 9119084. 7: Martin-de las Heras S, Valenzuela A, Villanueva E. Deoxypyridinoline crosslinks in human dentin and estimation of age. Int J Legal Med. 1999;112(4):222-6. PubMed PMID: 10433031. 8: Ohishi T, Takahashi M, Kawana K, Aoshima H, Hoshino H, Horiuchi K, Kushida K, Inoue T. Age-related changes of urinary pyridinoline and deoxypyridinoline in Japanese subjects. Clin Invest Med. 1993 Oct;16(5):319-25. PubMed PMID: 8261685. 9: Murata M, Tatsumi J, Kato Y, Suda S, Nunokawa Y, Kobayashi Y, Takeda H, Araki H, Shin K, Okuda K, Miyata T, Yoshie H. Osteocalcin, deoxypyridinoline and interleukin-1beta in peri-implant crevicular fluid of patients with peri-implantitis. Clin Oral Implants Res. 2002 Dec;13(6):637-43. PubMed PMID: 12519339. 10: Soylu H, Aras S, Kutlu NO, Egri M, Sahin K. Urinary excretion of deoxypyridinoline in 24-hour and first-void samples in healthy Turkish children. Clin Biochem. 2000 Jun;33(4):269-72. PubMed PMID: 10936584. 11: Bettica P, Baylink DJ, Moro L. Galactosyl hydroxylysine and deoxypyridinoline: a methodological comparison. Eur J Clin Chem Clin Biochem. 1993 Jul;31(7):459-65. PubMed PMID: 8399787. 12: Fassbender WJ, Gödde M, Brandenburg VM, Usadel KH, Stumpf UC. Urinary bone resorption markers (deoxypyridinoline and C-terminal telopeptide of type I collagen) in healthy persons, postmenopausal osteoporosis and patients with type I diabetes. Adv Med Sci. 2009;54(1):1-6. doi: 10.2478/v10039-009-0003-x. PubMed PMID: 19482729. 13: Topkan E, Karaoglu A. Urine calcium and deoxypyridinoline in assessment of response to local radiation therapy for metastatic bone disease. J Exp Clin Cancer Res. 2007 Dec;26(4):553-9. PubMed PMID: 18365552. 14: Sano M, Kushida K, Takahashi M, Ohishi T, Kawana K, Okada M, Inoue T. Urinary pyridinoline and deoxypyridinoline in prostate carcinoma patients with bone metastasis. Br J Cancer. 1994 Oct;70(4):701-3. PubMed PMID: 7917922; PubMed Central PMCID: PMC2033391. 15: Hoshino H, Takahashi M, Kushida K, Ohishi T, Kawana K, Inoue T. Quantitation of the crosslinks, pyridinoline, deoxypyridinoline and pentosidine, in human aorta with dystrophic calcification. Atherosclerosis. 1995 Jan 6;112(1):39-46. PubMed PMID: 7772065. 16: Iimura Y, Agata U, Takeda S, Kobayashi Y, Yoshida S, Ezawa I, Omi N. Lycopene intake facilitates the increase of bone mineral density in growing female rats. J Nutr Sci Vitaminol (Tokyo). 2014;60(2):101-7. PubMed PMID: 24975219. 17: Robins SP, Woitge H, Hesley R, Ju J, Seyedin S, Seibel MJ. Direct, enzyme-linked immunoassay for urinary deoxypyridinoline as a specific marker for measuring bone resorption. J Bone Miner Res. 1994 Oct;9(10):1643-9. PubMed PMID: 7817812. 18: Takeuchi S, Saitoh H. [The clinical usefulness of urinary pyridinoline and deoxypyridinoline as potential markers of bone metastasis in patients with prostate cancer]. Nihon Rinsho. 1998 Aug;56(8):2077-81. Japanese. PubMed PMID: 9750511. 19: Lietz G, Avenell A, Robins SP. Short-term effects of dietary sodium intake on bone metabolism in postmenopausal women measured using urinary deoxypyridinoline excretion. Br J Nutr. 1997 Jul;78(1):73-82. PubMed PMID: 9292761. 20: Hesley RP, Shepard KA, Jenkins DK, Riggs BL. Monitoring estrogen replacement therapy and identifying rapid bone losers with an immunoassay for deoxypyridinoline. Osteoporos Int. 1998;8(2):159-64. PubMed PMID: 9666940.